| Literature DB >> 28469695 |
Rongrong Yang1, Hong Zhang1, Yong Xiong1, Xien Gui1, Yongxi Zhang1, Liping Deng1, Shicheng Gao1, Mingqi Luo1, Wei Hou2, Deyin Guo2.
Abstract
BACKGROUND: CSF PCR is the standard diagnostic technique used in resource-rich settings to detect pathogens of the CNS infection. However, it is not currently used for routine CSF testing in China. Knowledge of CNS opportunistic infections among people living with HIV in China is limited.Entities:
Keywords: AIDS; Central nervous system diseases; Cerebrospinal fluid
Mesh:
Year: 2017 PMID: 28469695 PMCID: PMC5414136 DOI: 10.1186/s12981-017-0150-2
Source DB: PubMed Journal: AIDS Res Ther ISSN: 1742-6405 Impact factor: 2.250
Fig. 1Study profile
Patient demographics (N = 54)
| Feature | No (%) |
|---|---|
| Age (years), mean (SD) | 38 (11.2) |
| Male | 35 (64.8) |
| Occupation | |
| Farmers | 38 (70.4) |
| Clerk | 8 (14.8) |
| Businessman | 4 (7.4) |
| Others | 4 (7.4) |
| HIV transmission route | |
| Sex | 43 (79.6) |
| Blood donation/transfusion | 6 (11.1) |
| IDU | 2 (3.7) |
| Unknown | 3 (5.6) |
| Days since HIV diagnosis, median (IQR) | 45 (1–732) |
| CD4+ T cells/μl, median (IQR) | 31 (21–83) |
SD standard deviation
Characteristics of patients with CSF pathogen(s)
| Pathogens | Individual CSF prevalence | 1 pathogen | No. of cases | 2 pathogens | No. of cases | 3 pathogens | No. of cases |
|---|---|---|---|---|---|---|---|
| Cryptoa | 34/54 (63.0%) | Crypto | 22 | Crypto/CMV | 7 | Crypto/TB/CMV | 2 |
| Crypto/VZV | 1 | Crypto/TB/HHV-6 | 1 | ||||
| Crypto/JCV | 1 | ||||||
| CMV | 12/54 (22.2%) | CMV | 2 | CMV/TB | 1 | ||
| TB | 7/54 (13.0%) | TB | 3 | ||||
| Toxop | 5/54 (9.3%) | Toxop | 5 | ||||
| VZV | 2/54 (3.7%) | VZV | 1 | ||||
| JCV | 1/54 (1.9%) | JCV | 0 | ||||
| EBV | 1/54 (1.9%) | EBV | 1 | ||||
| HHV-6 | 1/54 (1.9%) | HHV-6 | 0 | ||||
| HSV | 0/54 (0%) | HSV | 0 | ||||
| Total | 63 pathogens | 34/54 (63.0%) | 10/54 (18.5%) | 3/54 (5.6%) |
Variables associate with death in univariate and multivariate analysis
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) |
| Odds ratio (95% CI) |
| |
| Categorical | ||||
| Male | 0.58 (0.30–1.32) | 0.26 | ||
| cART status | 0.48 (0.30–2.22) | 0.56 | ||
| Multiple pathogens | 0.33 (0.14–0.56) | <0.0001 | 0.46 (0.26–0.74) | 0.002 |
| Cryptococcal meningitis | 1.32 (0.80–2.34) | 0.22 | ||
| CMV | 1.21 (0.58–2.33) | 0.74 | ||
| Tuberculosis | 0.63 (0.88–3.26) | 0.30 | ||
| EBV | 0.70 (0.44–1.33) | 0.23 | ||
| Other pathogens | 0.85 (0.44–1.63) | 0.53 | ||
| Pathogen-based treatment | 5.7 (2.0–17.6) | <0.0001 | 4.8 (2.4–16.5) | 0.001 |
| Seizures | 0.87 (0.33–1.42) | 0.08 | 0.52 (0.36–0.98) | 0.04 |
| Intracranial hypertension | 0.27 (0.18–0.84) | 0.04 | 0.33 (0.22–0.84) | 0.03 |
| Disturbance of consciousness | 0.67 (0.43–1.04) | 0.06 | 1.00 (0.46–2.18) | 0.99 |
| Continuous | ||||
| Age | 0.36 (0.14–0.89) | 0.08 | 0.56 (0.32–1.02) | 0.25 |
| GCS | 0.22 (0.12–0.32) | <0.0001 | 0.42 (0.21–0.80) | 0.001 |
| CD4 count | 0.66 (0.45–1.24) | 0.68 | ||
GCS Glasgow coma scale